Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

Gilles Salles, Nicolas Mounier, Sophie de Guibert, +14

Blood

Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

Jean‐Luc Harousseau, Jean‐Yves Cahn, B. Pignon, +17

PubMed

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer

P. Fumoleau, R. Largillier, Christine Clippe, +12

European Journal of Cancer

Breast OncologyOncologyMedicinePhase Ii StudyBreast Cancer +4

Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

Philippe Moreau, Véronique Leblond, Priscille Bourquelot, +12

British Journal of Haematology

Prognostic FactorsCell TherapySystemic Al AmyloidosisImmunologyTransplantation Medicine +14

A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

Francis Witz, Alain Sadoun, M. C. Perrin, +17

PubMed

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled, +342

The Lancet

Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer +4

Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study

Éric Solary, Brigitte Witz, Denis Caillot, +14

Blood

Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial

Alain Ravaud, Robert D. Hawkins, Jason P. Gardner, +10

Journal of Clinical Oncology

Tumor necrosis factor α release is a major biological event associated with rituximab treatment

Jacques Bienvenu, Roland Chvetzoff, Gilles Salles, +13

The Hematology Journal

InflammationAutoimmune DiseaseMajor Biological EventImmune RegulationImmunology +8

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma

Emmanuel Bachy, Roch Houot, F. Morschhauser, +15

Haematologica